cinnarizine and Sleep-Wake-Disorders

This study aimed to investigate the clinical and cognitive side effects of baclofen (10 mg), meclizine (25 mg), dimenhydrinate (40 mg) plus cinnarizine (25 mg) and promethazine (25 mg) plus d-amphetamine (10 mg). The study had a double-blind, placebo controlled, repeated measures design and was conducted on healthy male volunteers. The psychomotor vigilance test, the Sternberg working memory task, the implicit memory test and the automated Operation Span (Ospan) task were performed. The Stanford, the Karolinska and the Epworth Sleepiness scale determined the degree of sleepiness. The Profile of Mood States (POMS) evaluated mood states and adverse effects were reported on a 22-item questionnaire. Letter recalls and time for solving mathematical problems, recorded during the Ospan task, were impaired by baclofen and dimenhydrinate-cinnarizine respectively, suggesting an influence of these drugs on the working memory. Significant side effects for baclofen were: sleepiness, tiredness, blurred vision, concentration problems and dizziness whereas for dimenhydrinate-cinnarizine only sleepiness and blurred vision were reported. Meclizine decreased the accuracy on the Sternberg working memory task and thus seemed to affect short-term memory. A reported side effect was increased sleepiness. Promethazine plus d-amphetamine did not affect any of the tested cognitive functions. However, many side effects such as sleepiness, dry mouth, dizziness, vertigo, confusion, insomnia and tremors were reported. The results show that meclizine and dimenhydrinate combined with cinnarizine were the two drugs with the most acceptable combination of side effects.

Topics: Adult; Antiemetics; Baclofen; Cinnarizine; Cognition; Cognition Disorders; Dimenhydrinate; Double-Blind Method; Healthy Volunteers; Humans; Male; Memory; Memory Disorders; Middle Aged; Motion Sickness; Neuropsychological Tests; Promethazine; Psychomotor Performance; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Young Adult

The results of a double blind trial in a total of 54 outpatients with cerebrovascular insufficiency are reported. With reference to objective test criteria (flicker frequency analysis and reaction test) and the change in the existing symptoms of this clinical picture the behavior of a new preparation, Cetal retard, was compared with the well-known drug (cinnarizine) with regard to the therapeutic efficacy on these symptoms. Although a therapeutic success was demonstrable in both groups after 21 days, Cetal retard was found to be significantly better in a number of the criteria tested.

Topics: Aged; Attention; Cerebrovascular Disorders; Cinnarizine; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Flicker Fusion; Headache; Humans; Male; Middle Aged; Piperazines; Reaction Time; Sleep Wake Disorders; Vertigo; Vinca Alkaloids